Skip to main content

2 Result(s)

within Medicine & Public Health Remove this filter Oncology Remove this filter Kageaki Taima Remove this filter Article Remove this filter

and

  1. Article

    Open Access

    A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

    This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring...

    Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga… in Medical Oncology (2018)

    Download PDF (671 KB) View Article

  2. Article

    Open Access

    Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

    Afatinib, a second-generation epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan in 2014. This study evaluated clinical...

    Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka… in Medical Oncology (2019)

    Download PDF (1007 KB) View Article